Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 36

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 36
---
,500,000; |

| • | are subject to redemption at our option upon the occurrence of certain tax related events, as described under the caption “—Tax Redemption;” |

| • | are subject to repurchase by us at the option of the holders following a fundamental change (as defined below under the caption “—Fundamental Change Permits Holders to Require Us to Repurchase Notes”), subject to certain conditions and limited exceptions, at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased,plusaccrued and unpaid interest to, but excluding, the fundamental change repurchase date; |

| • | are issued in minimum denominations of $1,000 and integral multiples of $1,000; and |

| • | are represented by one or more registered notes in global form, but in certain limited circumstances may be represented by notes in definitive form (see the caption “—Book-entry, Settlement and Clearance”). |

Prior to the close of business on the business day immediately preceding the maturity date, the notes may be converted at an initial conversion rate of 10.5601 ADSs, each representing as of the date of this prospectus supplement one ordinary share, per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $94.70 per ADS). The conversion rate is subject to adjustment if certain events occur. Upon conversion of a note, we will cause to be delivered ADSs and pay cash in lieu of any fractional ADS, as described under the caption “—Conversion Rights—Settlement upon Conversion;” providedthat, in certain circumstances described under the caption “—Conversion Rights—Conversion Share Limitations,” we may be required to settle conversions of notes in cash. A converting holder will not receive any separate cash payment for interest, if any, accrued and unpaid to the conversion date except under the limited circumstances described below.

S-22

#### TABLE OF CONTENTS
The indenture does not limit the amount of debt, including secured debt, that may be issued by us or our subsidiaries under the indenture or otherwise. The indenture does not contain any financial covenants and does not restrict us from paying dividends or issuing or repaying, prepaying or repurchasing our other securities or indebtedness. Other than restrictions described under the captions “—Fundamental Change Permits Holders to Require Us to Repurchase Notes” and “—Consolidation, Merger and Sale of Assets” below and except